Indian stocks: Visit www.stage2stocks.com →

Armata Pharmaceuticals, Inc.

Stage 4 · Declining · week 15

As of Oct 22, 2026, Armata Pharmaceuticals is in Stage 4, the downtrend phase, now in week 15 (since Jul 14, 2026). It closed at $3.45, 76.7% below its 52-week high and below its 200-day average, which is falling.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. More about the company

$3.45
+12.75% today
$128M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ARMP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 16w
S4 43w
S2 43w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S2 9w → S3 10w → S2 16w → S3 7w → S4 6w → S1 4w → S4 43w → S1 6w → S2 43w → S3 8w → S4 14w current
Total tracked: 166 weeks across 12 stage runs.

ARMP among Biotechnology190th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…190ARMPStage 4 · wk 1553−5.2%
vs 52W High
-76.7%
$2.78 lo$14.80 hi
76.7% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 15
1w13w26w
Week 15, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-51.5%
200 DMA: $7.11 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.50x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-5.2%
3M
-26.0%
6M
-74.5%
YTD
-47.4%
1Y
-0.6%
Scan Membership
Breakout Watch
Latest: 2023-12-29
7 appearances in last 60 days. First seen: 2019-08-29.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 15 · Vol 0.50x
2026-10-21S4
Wk 15 · Vol 0.42x
2026-10-20S4
Wk 14 · Vol 0.40x
2026-10-19S4
Wk 14 · Vol 0.41x
2026-10-16S4
Wk 14 · Vol 0.72x
2026-10-15S4
Wk 14 · Vol 0.54x
2026-10-14S4
Wk 14 · Vol 0.58x
2026-10-13S4
Wk 13 · Vol 1.04x
2026-10-12S4
Wk 13 · Vol 0.21x
2026-10-09S4
Wk 13 · Vol 0.47x
2026-10-08S4
Wk 13 · Vol 0.33x
2026-10-07S4
Wk 13 · Vol 0.49x
Moving averages & range
50 DMA
$4.33
200 DMA
$7.11
52W High
$14.80
52W Low
$2.78
5D Low
$3.06
Resistance levels (recent highs)
20d High
$3.86
60d High
$5.84
120d High
$9.85
250d High
$14.80
Next resistance
+11.9%
to 20d High
Dividend Yield
0.00%
P/B -0.6

Armata Pharmaceuticals: quick answers

What stage is Armata Pharmaceuticals in?

As of Oct 22, 2026, Armata Pharmaceuticals (ARMP) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 14, 2026 and is in week 15. What the four stages mean

Is Armata Pharmaceuticals in an uptrend?

No. Armata Pharmaceuticals is in a Stage 4 downtrend. It trades 51.5% below its 200-day average, which is falling.

How far is Armata Pharmaceuticals from its 52-week high?

Armata Pharmaceuticals closed at $3.45 on Oct 22, 2026, 76.7% below its 52-week high of $14.80. Its 52-week low is $2.78.

How has Armata Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Armata Pharmaceuticals is down 0.6% over the past year and down 47.4% so far in 2026.

Which sector and industry is Armata Pharmaceuticals in?

Armata Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.